Skip to main content
. 2014 Jul;5(7-8):261–272. doi: 10.18632/genesandcancer.24

Figure 4. CDK4/6 has additive activity with HER2/EGRF kinase inhibitors.

Figure 4

(A) BT474 and SKBR3 cells were treated with Lapatinib concurrently with PD-0332991. Apoptosis was detected by Annexin V staining (p<0.01). (B) SKBR3 cells were treated with Lapatinib in the presence/absence of PD-0332991 and the indicated proteins were detected by immunoblotting. (C) SKBR3 cells were treated with Her2/EGFR inhibitors Neratinib, Afatanib, and BMS-599626 at increasing concentration in the presence/absence of 1 μM PD-0332991. Viability was measured by cell-titer-glow. (D) MCF10/Her2 cells were treated with increasing concentration of BMS-599626 at increasing concentration in the presence/absence of 1 μM PD-0332991. Viability was measured by cell-titer-glow. MCF10/Her2 cells were treated with increasing concentration of BMS-599626 at 0, 0.1, 0.25, and 0.5 μM PD-0332991. Viability was measured by cell-titer-glow.